Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Dong Wan Seo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4971-834X; OpenAlex author ID A5044806903. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. Comparison of clinical features and pancreatic cancer risk between genetic mutations associated versus alcohol associated chronic pancreatitis. Last author DOI 10.1016/j.pan.2025.10.011↗
  2. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  3. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  4. Acute pancreatitis as an early sign of pancreatic cancer; a retrospective, matched cohort study. Co-author DOI 10.1080/00365521.2024.2414804↗
  5. EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observational open-label pilot study. Co-author DOI 10.1097/eus.0000000000000003↗
  6. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  7. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  8. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  9. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  10. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  11. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Co-author DOI 10.1016/j.gie.2019.06.032↗
  12. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  13. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… Co-author DOI 10.4103/eus.eus_16_19↗
  14. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  15. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  16. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Co-author DOI 10.5009/gnl17391↗
  17. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  18. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. First author DOI 10.1016/j.gie.2015.08.048↗
  19. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tae Jun Song · 13 shared papers, 2016–2026 · strength 1.48
  2. Changhoon Yoo · 11 shared papers, 2017–2025 · strength 1.31
  3. Dongwook Oh · 8 shared papers, 2016–2026 · strength 1.28
  4. Song Cheol Kim · 12 shared papers, 2012–2025 · strength 1.24
  5. Dae Wook Hwang · 11 shared papers, 2017–2025 · strength 1.21
  6. Do Hyun Park · 13 shared papers, 2012–2024 · strength 1.15
  7. Sang Soo Lee · 13 shared papers, 2012–2024 · strength 1.15
  8. Kyu‐pyo Kim · 10 shared papers, 2017–2025 · strength 1.08
  9. Ki Byung Song · 10 shared papers, 2017–2024 · strength 0.98
  10. Baek‐Yeol Ryoo · 9 shared papers, 2017–2024 · strength 0.85
  11. Jin‐hong Park · 8 shared papers, 2012–2024 · strength 0.75
  12. Myung‐Hwan Kim · 10 shared papers, 2012–2022 · strength 0.73
  13. Gunn Huh · 2 shared papers, 2024–2026 · strength 0.58
  14. Yoonchan Lee · 2 shared papers, 2024–2026 · strength 0.58
  15. Seung‐Mo Hong · 3 shared papers, 2018–2025 · strength 0.46
  16. Woohyung Lee · 4 shared papers, 2020–2023 · strength 0.43
  17. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  18. Hyehyun Jeong · 2 shared papers, 2024 · strength 0.39
  19. Jae Ho Byun · 2 shared papers, 2020–2025 · strength 0.32
  20. Jin Hee Kim · 2 shared papers, 2020–2025 · strength 0.31
  21. Seung Soo Lee · 2 shared papers, 2020–2025 · strength 0.31
  22. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  23. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
  24. Se Jin Choi · 1 shared paper, 2025 · strength 0.23
  25. Jong Keon Jang · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.